BIA reacts to Novavax COVID-19 Vaccine showing 89.3% Efficacy in UK Phase 3 Trial

Steve Bates OBE, Chief Executive of the BIA said: “This is an incredibly important development for the UK and the world in being able to tackle COVID-19. This announcement is down to the foresight and planning of the UK Government Vaccine Taskforce (VTF) with the UK playing a crucial role in the Novavax global clinical trial, with more than 15,000 UK citizens participating. 

“In six months the VTF has built a diverse portfolio of vaccine candidates that includes established vaccine platforms with proven safety profiles such as Novavax and Valneva, and newer but clinically advanced platforms, including Oxford/AstraZeneca, Pfizer/BioNTech, Janssen and Moderna. This multitude of vaccines will mean the UK will be well placed to combat variants and ensure that we have the necessary supply to vaccinate the UK population.

“This work shows again the strength of the UK life sciences and biotech sector which has been at the forefront of finding solutions to the COVID-19 pandemic whether in vaccines, diagnostics and therapies, as well as harnessing its incredible genomic capacity which is being used to full effect to spot new variants of the COVID-19 virus.”

ENDS

Notes to Editors

1. For more information please contact Jack Fellows, Communications and Media Manager on jfellows@bioindustry.org or 07825942934

2. To read the Novavax press release, please follow this link